Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

News & Events

News

Use the search feature below to stay up to date on our latest news stories.

Celerion Pledges Commitment to the Science-Based Targets Initiative (SBTi) Net-Zero Standard

12.04.24

Celerion’s US Pharmacies Expand On-Site Services, Ensure cGMP FDA Compliance for Phase 1 Investigational Drugs

07.17.24

Celerion Honored With Prestigious CRO Leadership Award for Ninth Consecutive Year 

06.05.24

Jo Goodman Joins Celerion as Vice President of Bioanalytical Services

05.07.24

Celerion Achieves Milestone With CLIA Certification for Its Bioanalytical Laboratory, Expanding Capabilities in Clinical Trials and Diagnostic Testing

02.06.24

Celerion Receives a 2023 CRO Leadership Award in All Categories for the Eighth Year Running

05.10.23

Celerion Expands Its Service Offering to Include GLP/GCP Compliant Molecular and Cell Biology Testing

11.10.22

CRO Leadership Award Goes to Celerion for a 7th Consecutive Year

06.15.22

Celerion Announces Investment in ADME Suite of Services

04.06.22

Celerion Expands Early Phase Clinical Pharmacology Units

03.08.22

Tackling the Complexity of Complex Generic Drug Development

06.08.21

Celerion Receives CRO Leadership Award for 6th Consecutive Year

06.01.21

Is Age Just a Number? Clinical Drug Development in Older Adults

04.19.21

Human Trials For Lyme Disease Shot Kickoff In Nebraska

04.07.21

Leveraging Innovative Technologies to Access Better Data More Efficiently and Cost-Effectively

07.08.20

Celerion Recognized as 2020 CRO Leadership Champion for Reliability and Receives CRO Leadership Award for Capabilities, Compatibility, Expertise, and Quality

06.19.20

Celerion Expands HRMS Metabolite Identification Capabilities for Full Service Metabolism Offering

06.08.20

Celerion Celebrates a Decade of Translating Science Into Medicine

03.10.20

Celerion Expands Clinical Research to Nebraska Innovation Campus

02.13.20

Newsletter: Q3/Q4 2019

12.17.19

NASH Pathway to Approval – Light at the End of the Tunnel

12.10.19

Celerion Celebrates 50th Anniversary of First Clinical Trial

07.17.19

Newsletter: Q2 2019

07.11.19

Celerion Recognized as a Leading Contract Research Organization for the 4th Consecutive Year

03.27.19

Newsletter: Q1 2019

03.07.19

Newsletter: Q2 2018

03.07.19

Newsletter: Q3/Q4 2018

09.01.18

Biopharmaceutical Industry Recognizes Celerion as a Leading Contract Research Organization

04.03.18

Newsletter: Q2 2018

04.01.18

Industry Leading Nicotine Researcher Joins Celerion Research Team

01.23.18

Celerion Creates a Fully Automated, Early Development Clinical Trial Data Management Platform

01.16.18

Newsletter: Q1 2018

01.01.18

Newsletter: Q4 2017

10.01.17

Newsletter: Q3 2017

07.01.17

Celerion Receives a 2017 CRO Leadership Award in Multiple Categories for Clinical Research Excellence

06.19.17

Newsletter: Q2 2017

04.01.17

Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials

03.14.17

Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer

02.22.17

Newsletter: Q1 2017

01.01.17

Celerion Announces Celexus as a Premier Safety Reporting Tool for Phase I Clinical Trials

11.17.16

Celerion Named Best Translational Clinical Pharmacology Company 2016

10.05.16

Newsletter: Q4 2016

10.01.16

Celerion Recognized by Biopharmaceutical Clients as a Leader in Contract Research Quality Benchmarking Survey

05.26.16

Assign Clinical Research Joins Celerion

01.11.16

Celerion Expands its Cell-Based Assays Capabilities in Global Bioanalytical Services

11.03.14

Celerion Completes Recapitalization Through Investment by MTS Capital Health Partners

10.29.14

Celerion Announces Membership into the Cardiac Safety Research Consortium (CSRC)

10.15.14

Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen’s University, Belfast

09.30.14

Celerion Appoints Dr. Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services

06.16.14

Celerion Selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium for The Beta Cell Project

06.11.14

Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Research in South Korea

05.28.14

Celerion Opens Operations in South Korea at Seoul National University Hospital Clinical Trial Center

03.04.14

Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska

12.17.13

Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations

12.05.13

Celerion Appoints Clayton Dehn as Executive Director, Metabolic Diseases

11.05.13

Celerion Expands Belfast Facility with Containment Room to Enable Live Biologics and Vaccine Studies

06.04.13

Celerion appoints Dr. Bruce Morimoto as Executive Director, Applied Translational Medicine

05.21.13

Types and Features of NDA Enabling

02.25.13

Celerion Builds on Respiratory Capabilities With the Addition of an On-site Bronchoscopy Suite

01.09.13

Celerion is the First CRO Headquartered in the USA to Receive Full Accreditation from AAHRPP

09.17.12

Celerion announces expanded state-of-the-art ADME Suite in its Lincoln, Nebraska USA facility

05.17.12

Celerion and Ricerca Biosciences announces “The Biosimilars Alliance” to offer clients a more effective development path for biosimilars

02.29.12

Celerion First Early Stage Contract Research Organization to Adopt a Participant Verification System to Improve Participant Safety and Data Quality

02.02.12

Celerion scientist proud recipient of Scientific and Technological Achievement Award (STAA) from EPA

01.11.12

Celerion receives license enabling Investigational Medicinal Products (IMPs) to be imported directly to their GMP-licensed facility

09.07.11

Celerion appoints Dr. Raymond Farmen as Vice President of Global Bioanalytical Services

06.29.11

Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples

06.21.11

Celerion announces highly automated ECG analysis enabling data delivery within 37 days from first patient dosed

06.20.11

Celerion receives ANVISA certification

06.09.11

Celerion awarded prestigious LEED® Green Building Certification

05.26.11

Member of UK Respiratory Therapeutic Capability Cluster

03.28.11

Celerion recognized as member of the UK Respiratory Therapeutic Capability Cluster

03.28.11

Celerion adds USP Clean Room, enabling efficient execution of microtracer and microdosing studies

03.02.11

Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies

12.09.10

Celerion launches electronic laboratory notebook, achieving major milestone toward 100% paperless laboratories

11.12.10

Celerion launches new Hybrid ECG Core Lab for Phase I clinics

06.02.10

Celerion acquires early stage clinical research operations from MDS Pharma Services

03.29.10

Tue Apr 24, 2012 Webinar: Discerning Early Clinical Signals of Efficacy for Treating Respiratory Diseases

03.28.10

Tue Mar 20, 2012 Webinar: Challenges in Early Comparability Assessment of Biosimilars

02.01.10

Load More